Knight Therapeutics Inc. (KHTRF)
OTCMKTS · Delayed Price · Currency is USD
4.040
0.00 (0.00%)
Oct 29, 2024, 4:00 PM EDT

Knight Therapeutics Statistics

Total Valuation

Knight Therapeutics has a market cap or net worth of 406.28 million. The enterprise value is 332.14 million.

Market Cap 406.28M
Enterprise Value 332.14M

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date Nov 8, 2024
Ex-Dividend Date n/a

Share Statistics

Shares Outstanding n/a
Shares Change (YoY) -7.80%
Shares Change (QoQ) +0.15%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 86.23M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.97, with an EV/FCF ratio of 7.50.

EV / Earnings -21.42
EV / Sales 1.37
EV / EBITDA 7.97
EV / EBIT 57.78
EV / FCF 7.50

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.08.

Current Ratio 3.41
Quick Ratio 2.38
Debt / Equity 0.08
Debt / EBITDA 1.00
Debt / FCF 0.96
Interest Coverage 0.69

Financial Efficiency

Return on equity (ROE) is -2.70% and return on invested capital (ROIC) is 0.59%.

Return on Equity (ROE) -2.70%
Return on Assets (ROA) 0.51%
Return on Capital (ROIC) 0.59%
Revenue Per Employee 340,506
Profits Per Employee -21,391
Employee Count 725
Asset Turnover 0.34
Inventory Turnover 1.72

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +23.17% in the last 52 weeks. The beta is 0.50, so Knight Therapeutics's price volatility has been lower than the market average.

Beta (5Y) 0.50
52-Week Price Change +23.17%
50-Day Moving Average 4.25
200-Day Moving Average 4.04
Relative Strength Index (RSI) 20.41
Average Volume (20 Days) 1,720

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Knight Therapeutics had revenue of 246.87 million and -15.51 million in losses. Loss per share was -0.15.

Revenue 246.87M
Gross Profit 119.41M
Operating Income 5.85M
Pretax Income -17.31M
Net Income -15.51M
EBITDA 40.48M
EBIT 5.85M
Loss Per Share -0.15
Full Income Statement

Balance Sheet

The company has 115.05 million in cash and 42.46 million in debt, giving a net cash position of 75.40 million.

Cash & Cash Equivalents 115.05M
Total Debt 42.46M
Net Cash 75.40M
Net Cash Per Share n/a
Equity (Book Value) 557.34M
Book Value Per Share 5.50
Working Capital 186.15M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 45.96 million and capital expenditures -1.65 million, giving a free cash flow of 44.31 million.

Operating Cash Flow 45.96M
Capital Expenditures -1.65M
Free Cash Flow 44.31M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross margin is 48.37%, with operating and profit margins of 2.37% and -6.28%.

Gross Margin 48.37%
Operating Margin 2.37%
Pretax Margin -7.01%
Profit Margin -6.28%
EBITDA Margin 16.40%
EBIT Margin 2.37%
FCF Margin 17.95%

Dividends & Yields

Knight Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 7.80%
Shareholder Yield 7.80%
Earnings Yield n/a
FCF Yield n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Knight Therapeutics has an Altman Z-Score of 2.69. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.69
Piotroski F-Score n/a